• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (30)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Neurology  • Multiple Sclerosis/ Demyelinating Disease  • Drug Therapy  • Adverse Effects  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Maria del Pilar Martin, PhD; Petra D. Cravens, PhD; Ryan Winger; Elliot M. Frohman, MD, PhD; Michael K. Racke, MD; Todd N. Eagar, PhD; Scott S. Zamvil, MD, PhD; Martin S. Weber, MD; Bernhard Hemmer, MD; Nitin J. Karandikar, MD, PhD; B. K. Kleinschmidt-DeMasters, MD; Olaf Stüve, MD, PhD

Arch Neurol. 2008;65(12):1596-1603. Published online October 13, 2008 (doi:10.1001/archneur.65.12.noc80051).

Objective  To extend our studies on the prolonged and differential effect of natalizumab on T lymphocyte numbers in the cerebrospinal fluid, we investigated the number and phenotypes of leukocytes and the expression of major histocompatibility complex (MHC) classes I and II in cerebral perivascular spaces (CPVS). We hypothesized that natalizumab reduces the number of antigen presenting cells in CPVS.

Design  A case-control study in which inflammatory cell numbers in the CPVS of cerebral tissue were assessed by immunohistochemical staining.

Subjects  A patient with multiple sclerosis (MS) who developed progressive multifocal leukoencephalopathy (PML) during natalizumab therapy. Controls included location-matched cerebral autopsy material of patients without disease of the central nervous system, patients with MS not treated with natalizumab, and patients with PML not associated with natalizumab therapy.

Results  The absolute number of CPVS in the patient with MS treated with natalizumab was significantly lower than in the control groups owing to extensive destruction of the tissue architecture. The expression of MHC class II molecules and the number of CD209⁺ dendritic cells were significantly decreased in the CPVS of the patient with MS treated with natalizumab. No CD4⁺ T cells were detectable.

Conclusions  Our observations may explain the differential and prolonged effects of natalizumab therapy on leukocyte numbers in the cerebrospinal fluid.

Author Affiliations: Departments of Neurology (Drs Martin, Cravens, Frohman, Eagar, and Stüve and Mr Winger), Ophthalmology (Dr Frohman), Immunology (Drs Eagar, Karandikar, and Stüve), and Pathology (Dr Karandikar), University of Texas Southwestern Medical Center at Dallas; Departments of Neurology, The Ohio State University Medical Center, Columbus (Dr Racke), University of California, San Francisco (Drs Zamvil and Weber), and Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany (Drs Weber and Hemmer); Departments of Pathology, Neurology, and Neurosurgery, University of Colorado, Denver (Dr Kleinschmidt-DeMasters); and the Neurology Section, Veterans Affairs North Texas Health Care System, Medical Service, Dallas (Dr Stüve).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

This Month in Archives of Neurology
Arch Neurol. 2008;65(12):1564-1565.
FULL TEXT  

Central Nervous System Immune Surveillance: On Natalizumab, Dendritic Cells, and Dangerous Immune Privilege
Burkhard Becher
Arch Neurol. 2008;65(12):1566-1567.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Th17 lymphocytes traffic to the central nervous system independently of {alpha}4 integrin expression during EAE
Rothhammer et al.
JEM 2011;208:2465-2476.
ABSTRACT | FULL TEXT  

Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome
Aly et al.
Brain 2011;134:2687-2702.
ABSTRACT | FULL TEXT  

CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment
Frisullo et al.
Mult Scler 2011;17:556-566.
ABSTRACT | FULL TEXT  

Translational Research in Neurology and Neuroscience 2010: Multiple Sclerosis
Stuve et al.
Arch Neurol 2010;67:1307-1315.
ABSTRACT | FULL TEXT  

Natalizumab and Progressive Multifocal Leukoencephalopathy: What Are the Causal Factors and Can It Be Avoided?
Warnke et al.
Arch Neurol 2010;67:923-930.
ABSTRACT | FULL TEXT  

{alpha}4{beta}1 Integrin Mediates the Recruitment of Immature Dendritic Cells across the Blood-Brain Barrier during Experimental Autoimmune Encephalomyelitis
Jain et al.
J. Immunol. 2010;184:7196-7206.
ABSTRACT | FULL TEXT  

Progressive Multifocal Leukoencephalopathy: What's New?
Focosi et al.
Neuroscientist 2010;16:308-323.
ABSTRACT  

Monoclonal antibodies in MS: Mechanisms of action
Bielekova and Becker
Neurology 2010;74:S31-S40.
ABSTRACT | FULL TEXT  

The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-{alpha}4{beta}7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Soler et al.
J. Pharmacol. Exp. Ther. 2009;330:864-875.
ABSTRACT | FULL TEXT  

Emerging Viral Infections of the Central Nervous System: Part 2
Tyler
Arch Neurol 2009;66:1065-1074.
ABSTRACT | FULL TEXT  

Depletion of B Lymphocytes From Cerebral Perivascular Spaces by Rituximab
Martin et al.
Arch Neurol 2009;66:1016-1020.
ABSTRACT | FULL TEXT  

Multiple sclerosis therapeutics: Unexpected outcomes clouding undisputed successes
Wiendl and Hohlfeld
Neurology 2009;72:1008-1015.
ABSTRACT | FULL TEXT  

Natalizumab in the treatment of multiple sclerosis.
Yaldizli and Putzki
Therapeutic Advances in Neurological Disorders 2009;2:115-128.
ABSTRACT  

Central Nervous System Immune Surveillance: On Natalizumab, Dendritic Cells, and Dangerous Immune Privilege
Becher
Arch Neurol 2008;65:1566-1567.
FULL TEXT